<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758338</url>
  </required_header>
  <id_info>
    <org_study_id>VICC PED 2013</org_study_id>
    <secondary_id>R01CA240093-01</secondary_id>
    <nct_id>NCT04758338</nct_id>
  </id_info>
  <brief_title>Enhancing Cancer Care Of Rural Dwellers</brief_title>
  <acronym>ENCORE</acronym>
  <official_title>Enhancing Cancer Care Of Rural Dwellers Through Telehealth and Engagement (ENCORE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debra Friedman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through a multi-level remote intervention, the Vanderbilt-Ingram Cancer Center (VICC) seeks&#xD;
      to improve comprehensive cancer care delivery to patients residing in rural communities with&#xD;
      persistent poverty. We plan to do this by using telehealth to broaden the reach of our&#xD;
      NCI-designated comprehensive cancer center in these communities&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
        -  Evaluate the clinical effectiveness of a multi-level telehealth-based intervention for&#xD;
           rural hospitals consisting of provider access to tumor board expertise that incorporates&#xD;
           disease, patient and molecular tumor characteristics, together with patient access to a&#xD;
           supportive care intervention to improve cancer care delivery.&#xD;
&#xD;
        -  Evaluate the facilitators and barriers to future larger-scale dissemination and&#xD;
           implementation of the multi-level intervention, designed to enhance quality rural cancer&#xD;
           care delivery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 2031</completion_date>
  <primary_completion_date type="Anticipated">December 2030</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the effectiveness of a multi-level telehealth-based intervention</measure>
    <time_frame>Approximately 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the facilitators to a future large-scale multi-level intervention</measure>
    <time_frame>Approximately 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the barriers to a future large-scale multi-level intervention</measure>
    <time_frame>Approximately 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>CTS Program Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-week intervention delivered via telehealth using the VUMC telehealth services.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Education Attention Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive educational materials either online, by email, or in print form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VUMC telehealth services</intervention_name>
    <description>Participants will access the CTS link (sent to them via email), which will connect them directly to a videoconference and enable them to see and hear the facilitators and other patients in the group.</description>
    <arm_group_label>CTS Program Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interview</intervention_name>
    <description>25-30 participants will be interviewed</description>
    <arm_group_label>CTS Program Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Educational materials</intervention_name>
    <description>Participants will be provided educational materials</description>
    <arm_group_label>Education Attention Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Provider and Patient:&#xD;
&#xD;
        - At least 21 years of age or older and English speaking with the ability to provide&#xD;
        informed consent&#xD;
&#xD;
          -  Oncology providers within designated VHAN oncology practices&#xD;
&#xD;
          -  Newly diagnosed or relapsed cancer patients of aforementioned oncology providers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emma Schremp</last_name>
    <phone>(615)936-2156</phone>
    <email>emma.schremp@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
    <phone>800-811-8480</phone>
    <email>cip@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baptist Cancer Center- Golden Triangle Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Mississippi</state>
        <zip>39705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Baty</last_name>
      <phone>662-244-1760</phone>
    </contact>
    <investigator>
      <last_name>Phil Lammers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Center - North Mississippi</name>
      <address>
        <city>Oxford</city>
        <state>Mississippi</state>
        <zip>38655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Mathews</last_name>
      <phone>662-636-4301</phone>
    </contact>
    <investigator>
      <last_name>Phil Lammers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Center- Bartlett</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>: Talana Vogel</last_name>
      <phone>901-226-3019</phone>
    </contact>
    <investigator>
      <last_name>Phil Lammers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Debra Friedman</investigator_full_name>
    <investigator_title>Sponsor Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

